Table 2 Treatment duration for isolated thoracic tuberculosis (TB) according to the type of treatment, and for extrathoracic TB according to the disease location.
Type of patients | Treatment duration (months) | ||||
|---|---|---|---|---|---|
6 | 6-9 | 9-12 | 12-18 | > 18 | |
Isolated thoracic TB, N = 279 | 163 (58.4%)* | 46 (16.5%) | 58 (20.8%) | 10 (3.6%) | 2 (0.7%) |
Four-drug regimen, N = 241 | 146 (60.6%) | 30 (12.5%) | 53 (22.0%) | 10 (4.1%) | 2 (0.8%) |
Three-drug regimen without ethambutol, N = 23 | 14 (60.9%) | 7 (30.4%) | 2 (8.7%) | - | - |
Three-drug regimen without pyrazinamide, N = 8 | 3 (37.5%) | 2 (25.0%) | 3 (37.5%) | - | - |
Four drug regimen and isoniazid resistance, N = 7 | 7 (100%) | ||||
Extrathoracic TB N = 199 | 53 (26.6%) | 34 (17.1%) | 57 (28.7%) | 44 (22.1%) | 11 (5.5%) |
Meningeal, N = 7 | 2 (28.6%) | 0 | 2 (28.6%) | 3 (42.8%) | - |
Isolated nodal, N = 98 | 34 (34.7%) | 18 (18.4%) | 29 (29.5%) | 13 (13.3%) | 4 (4.1%) |
Isolated osteoarticular, N = 22 | 2 (9.1%) | 2 (9.1%) | 6 (27.3%) | 9 (40.9%) | 3 (13.6%) |
Disseminated or military, N = 41 | 6 (14.6%) | 4 (9.8%) | 11 (26.8%) | 16 (39.0%) | 4 (9.8%) |
Other, N = 31 | 9 (29.0%) | 10 (32.3%) | 9 (29.0%) | 3 (9.7%) | - |